CA
NZ
UK
AU
IND
US
Alphatec is a spine-focused medical device company operating through Alphatec Spine, EOS imaging and SafeOp Surgical. It sells procedural solutions and a surgical technology platform to spine surgeons. Its fiscal third quarter ended September 30, 2026.
Atossa is a clinical-stage biopharmaceutical company focused on oncology. Its lead candidate is oral (Z)-endoxifen, a selective estrogen receptor modulator and degrader being studied in Phase 2 trials for breast cancer treatment and risk reduction. The company was formerly known as Atossa Genetics.
The same announcement said stockholders approved converting the Series A preferred stock issued in the June 2026 acquisition of Azora into common stock, subject to beneficial ownership limits. A new executive team was also named. No separate announcement tied to today's decline was identified, …
BrightSpring provides home and community-based services for medically complex populations through pharmacy, home health and rehabilitation operations. The company says it serves roughly 500,000 customers, clients and patients each day across all 50 states.
CareDx develops testing and digital tools for transplant patients and their care teams, including AlloSure Kidney, which looks for signs of graft injury. Testing Services revenue climbed 65% to $119.2 million, including $12 million from its Specialty Oncology business.
CDT Equity describes itself as a data-driven biopharmaceutical company that identifies, enhances and monetizes therapeutic assets. Its pipeline includes AZD1656, in Phase II for autoimmune disorders, AZD5658, in Phase I for Type 2 diabetes, and AZD5904, which has completed Phase I for idiopathic male …
The 52-week range runs from $1.62 to $16.50, reflecting theVolatilitythat has followed a 1-for-15 reverse split in June 2025 and a major restructuring of the business.
The most recent company-specific news was the October 19 announcement that the FDA accepted a supplemental new drug application for REZZAYO, seeking an added indication for prevention of invasive fungal disease. The application received priority review. Earlier guidance from the company had pointed to …
The company said its ordinary shares were expected to start trading on the Nasdaq Global Market on October 22, 2026. A data provider showed the stock at $4.04 on October 26, down from a $6.00 prior close, which means today's price of $1.93 sits …
● The 2026 adjusted EBITDA outlook was lowered to no less than $100 million.
Please wait processing your request...